USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
ELSOHLY LABORATORIES, INC.
Address:
5 INDUSTRIAL PARK DR
OXFORD, MS 38655-
Phone:
N/A
URL:
N/A
EIN:
164071232
DUNS:
157239245
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $382,169.00 6
SBIR Phase II $1,249,917.00 3
STTR Phase I $672,841.00 6
STTR Phase II $1,759,160.00 3

Award List:

DEVELOPMENT OF A NEW DOSAGE FORM FOR LONG-TERM STUDIES OF ^9-THC

Award Year / Program / Phase:
1986 / SBIR / Phase I
Award Amount:
$43,000.00
Agency:
HHS
Principal Investigator:
M A Elsohly , Principal Investigator
Abstract:
N/a

DEVELOPMENT OF A CANNABIS FINGERPRINT

Award Year / Program / Phase:
1987 / SBIR / Phase I
Award Amount:
$48,000.00
Agency:
HHS
Principal Investigator:
Mahmoud a el sohly phd
Abstract:
This project intends to study the feasibility of developing analytical procedures to be used for identifying the countryof origin of a given cannabis sample on the basis of its chemical profile. gas chromatography/mass spectrometry (gc/ms) will be the main technique used in the development of such… More

DEVELOPMENT OF A NEW DOSAGE FORM FOR LONG-TERM STUDIES OF ^9-THC

Award Year / Program / Phase:
1988 / SBIR / Phase II
Award Amount:
$252,000.00
Agency:
HHS
Principal Investigator:
M A Elsohly , Principal Investigator
Abstract:
Studies in this proposal will be aimed at the preparation ofa suppository formulation of a pro-drug of delta-9-tetra- hydrocannabinol (^9-thc) and study the bioavailability of thc from this formulation as compared to i.v. administrationof both thc and its prodrug. bioavailability studies will be… More

IDENTIFY/ANALYZE THC AND COCAINE METABOLITES IN MECONIUM

Award Year / Program / Phase:
1996 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

IDENTIFY/ANALYZE THC AND COCAINE METABOLITES IN MECONIUM

Award Year / Program / Phase:
1997 / SBIR / Phase II
Award Amount:
$315,780.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

PRECLINICAL DEVELOPMENT OF A NEW DRUG FOR PCP

Award Year / Program / Phase:
1998 / STTR / Phase I
Award Amount:
$99,886.00
Agency:
HHS
Principal Investigator:
Clark
Research Institution:
University of Mississippi
RI Contact:
N/A
Abstract:
N/a

N/A

Award Year / Program / Phase:
1999 / SBIR / Phase I
Award Amount:
$97,353.00
Agency:
HHS
Principal Investigator:
M. A. Elsohly
Abstract:
Not Available Accurate Automation Corporation (AAC) will apply the latest knowledge in optimal control, adaptive control, and learning control to develop a state-of-the-art, adaptive, nonlinear, package for robust satellite guidance and control. The guidance module will generate an optimal… More

N/A

Award Year / Program / Phase:
2000 / STTR / Phase I
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
Clark
Research Institution:
University of Mississippi
RI Contact:
N/A
Abstract:
N/a

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase I
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
Mamoud Elsohly
Abstract:
N/a

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase II
Award Amount:
$682,137.00
Agency:
HHS
Principal Investigator:
Mamoud Elsohly
Abstract:
N/a

SYNTHESIS OF CONJUGATED METABOLITES OF BUPRENOPHINE

Award Year / Program / Phase:
2002 / SBIR / Phase I
Award Amount:
$93,816.00
Agency:
HHS
Principal Investigator:
Abstract:
The development of maintenance treatment for subjects with addictive behavior is an important public health issue. Buprenorphine, a promising new drug for the treatment of opiates addition, has been widely abused since the mid-90's. Using drug testing for buprenorphine will become an important… More

Transmucosal Intra-Oral Drug Delivery System for THC

Award Year / Program / Phase:
2003 / STTR / Phase I
Award Amount:
$99,986.00
Agency:
HHS
Principal Investigator:
Research Institution:
UNIVERSITY OF MISSISSIPPI
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): The overall goal of this research project is to develop an effective, hot-melt extruded "Transmucosal Matrix Patch" (TMP) as a delivery system for Delta-9-Tetrahydrocannabinol (THC). THC will be incorporated into a stable, bioadhesive drug delivery system that is… More

Compositions for Prevention/Prophylactic Treatment of Poison Ivy Dermatitis

Award Year / Program / Phase:
2006 / STTR / Phase I
Award Amount:
$100,074.00
Agency:
HHS
Principal Investigator:
Research Institution:
UNIVERSITY OF MISSISSIPPI
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): The long term objectives of this proposal are aimed at the development of new composition(s) to be used for the prophylactic treatment/prevention of poison ivy contact dermatitis in sensitive individuals. Poison ivy/poison oak and another related species poison… More

Transmucosal Intra-Oral Drug Delivery System for THC

Award Year / Program / Phase:
2008 / STTR / Phase II
Award Amount:
$743,609.00
Agency:
HHS
Principal Investigator:
Research Institution:
N/A
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): Delta-9-Tetrahydrocannabinol (THC), the active ingredient in the cannabis plant, has a wide range of pharmacological properties of therapeutic value. The drug has been approved by the Food and Drug Administration (FDA) (Marinol(r) soft gelatin capsules) for the… More

Compositions for Prevention/Prophylactic Treatment of Poison Ivy Dermatitis

Award Year / Program / Phase:
2009 / STTR / Phase II
Award Amount:
$739,218.00
Agency:
HHS
Principal Investigator:
Research Institution:
UNIVERSITY OF MISSISSIPPI
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): Poison ivy/oak contact dermatitis is the most prevalent skin allergy in the United States, affecting gt50% of the adult population. The condition is the major cause of occupational hazard among outdoor workers in fores try, agriculture and firefighting,… More

Development of Tetrahydrocannabinol Prodrugs for Topical Treatment of Glaucoma

Award Year / Program / Phase:
2011 / STTR / Phase I
Award Amount:
$167,381.00
Agency:
HHS
Principal Investigator:
Mahmoud A. Elsohly – 662-236-2609
Research Institution:
THE UNIVERSITY OF MISSISSIPPI
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): Currently, FDA approved clinical applications of 9-Tetrahydrocannabinol (THC) include control of nausea and vomiting associated with chemotherapy and for appetite stimulation for AIDS patients suffering from anorexia and wasting syndrome. However, THC also… More

Orally Active Formulations of DHA Dimers for the Treatment of Infectious Diseases

Award Year / Program / Phase:
2013 / STTR / Phase I
Award Amount:
$205,514.00
Agency:
HHS
Principal Investigator:
Mahmoud A. Elsohly – 662-236-2609
Research Institution:
UNIVERSITY OF MISSISSIPPI
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): The natural product artemisinin is a sesquiterpene endoperoxide with known anti-malarial activity against both chloroquine-sensitive and chloroquine-resistant strains of the parasite Plasmodium falciparum. In addition to its anti-malarial activity, artemisinin… More